ArticleInflammatory bowel diseases2020
Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease.
Article in Inflammatory bowel diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Venous Thromboembolism Prophylaxis in Inflammatory Bowel Disease Inpatients: Systematic Review and Meta-Analysis.Acta haematologica · 2024Pooled it
- The Incidence and Characteristics of Venous Thromboembolisms in Paediatric-Onset Inflammatory Bowel Disease: A Prospective International Cohort Study Based on the PIBD-SETQuality Safety Registry.Journal of Crohn's & colitis · 2022Pooled it
- Risk factors for early-onset venous thromboembolism in pediatric inflammatory bowel disease.Crohn's & colitis 360 · 2026Article
- Comparing characteristics and outcomes in admissions with pulmonary embolism and inflammatory bowel disease: a national cohort study.Proceedings (Baylor University. Medical Center) · 2026Article
- Role of Post-discharge Venous Thromboembolism Prophylaxis after Colorectal Surgery.Clinics in colon and rectal surgery · 2026Review
- Predicting Outcomes in Hospitalized Patients With Acute Severe Ulcerative Colitis in a Prospective Multicenter Cohort.Inflammatory bowel diseases · 2025Observational
- Common Mistakes in Managing Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2024Review
- Oral TNF-α siRNA delivery via milk-derived exosomes for effective treatment of inflammatory bowel disease.Bioactive materials · 2024Article
- Subtypes of Venous Thromboembolism in Inflammatory Bowel Disease: A Nationwide Assessment.Clinical research and clinical trials · 2024Article
- Venous Thromboembolism in Patients with Inflammatory Bowel Disease.Journal of clinical medicine · 2023Review
- Cardiovascular implications of inflammatory bowel disease: An updated review.World journal of cardiology · 2023Review
- Risk assessment of venous thromboembolism in inflammatory bowel disease by inherited risk in a population-based incident cohort.World journal of gastroenterology · 2023Article
- Increasing rates of venous thromboembolism among hospitalised patients with inflammatory bowel disease: a nationwide analysis.Alimentary pharmacology & therapeutics · 2022Article
- Article
- Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease.Inflammatory bowel diseases · 2022Article
- Article
- Venous Thromboembolic Complications in Pediatric Gastrointestinal Diseases: Inflammatory Bowel Disease and Intestinal Failure.Frontiers in pediatrics · 2022Review
- International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2021Article
- Venous and arterial thromboembolism in patients with inflammatory bowel diseases.World journal of gastroenterology · 2021Review
- Cerebral venous sinus thrombosis in patients with inflammatory bowel disease: a retrospective study.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundDespite increased risk of venous thromboembolism (VTE) among hospitalized patients with inflammatory bowel disease (IBD), pharmacologic prophylaxis rates remain low. We sought to understand the reasons for this by assessing factors associated with VTE prophylaxis in patients with IBD and the safety of its use.
methodsThis was a retrospective cohort study conducted among patients hospitalized between January 2013 and August 2018. The primary outcome was VTE prophylaxis, and exposures of interest included acute and chronic bleeding. Medical records were parsed electronically for covariables, and logistic regression was used to assess factors associated with VTE prophylaxis.
resultsThere were 22,499 patients studied, including 474 (2%) with IBD. Patients with IBD were less likely to be placed on VTE prophylaxis (79% with IBD, 87% without IBD), particularly if hematochezia was present (57% with hematochezia, 86% without hematochezia). Among patients with IBD, admission to a medical service and hematochezia (adjusted odds ratio 0.27; 95% CI, 0.16-0.46) were among the strongest independent predictors of decreased VTE prophylaxis use. Neither hematochezia nor VTE prophylaxis was associated with increased blood transfusion rates or with a clinically significant decline in hemoglobin level during hospitalization.
conclusionHospitalized patients are less likely to be placed on VTE prophylaxis if they have IBD, and hematochezia may drive this. Hematochezia appeared to be minor and was unaffected by VTE prophylaxis. Education related to the safety of VTE prophylaxis in the setting of minor hematochezia may be a high-yield way to increase VTE prophylaxis rates in patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.